This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Syed, D. N. Articles by Mukhtar, H. Search for Related Content PubMed PubMed Citation Articles by Syed, D. N. Articles by Mukhtar, H. Related Collections Review Epidemiology and Prevention Epidemiology and Prevention: Nutrition

Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise

Department of Dermatology, University of Wisconsin, Madison, Wisconsin

Requests for reprints: Hasan Mukhtar, Department of Dermatology, University of Wisconsin, Medical Sciences Center, Room B25, 1300 University Avenue, Madison, WI 53706. Phone: 608-263-3927; Fax: 608-263-5223. E-mail: hmukhtar{at}wisc.edu

Prostate cancer (CaP) is second only to lung cancer as the cause of cancer-related deaths in American men and is responsible for over 29,000 deaths per year. One promising approach to reduce the incidence of CaP is through chemoprevention, which has been recognized as a plausible and cost-effective approach to reduce cancer morbidity and mortality by inhibiting precancerous events before the occurrence of clinical disease. Indeed, CaP is an ideal candidate disease for chemoprevention because it is typically diagnosed in the elderly population with a relatively slower rate of growth and progression, and therefore, even a modest delay in the development of cancer, achieved through pharmacologic or nutritional intervention, could result in substantial reduction in the incidence of clinically detectable disease. In this review, we have summarized the recent investigations and mechanistic studies on CaP chemoprevention using dietary agents, such as selenium, vitamins D and E, lycopene, phytoestrogens, flavonoids, and green tea polyphenols. Well-designed trials are required to delineate the potential clinical usefulness of these agents through issues, such as determining the optimal period and route of administration, systemic bioavailability, optimal dosing and toxicity of the agent, and single or combinatorial approach. It is hoped that, combining the knowledge based on agents with targets, effective approaches for CaP chemoprevention can be established. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2193–204)

This article has been cited by other articles:

				N. Khan, M. Asim, F. Afaq, M. Abu Zaid, and H. Mukhtar A Novel Dietary Flavonoid Fisetin Inhibits Androgen Receptor Signaling and Tumor Growth in Athymic Nude Mice Cancer Res., October 15, 2008; 68(20): 8555 - 8563. [Abstract] [Full Text] [PDF]

				B. B. Hafeez, I. A. Siddiqui, M. Asim, A. Malik, F. Afaq, V. M. Adhami, M. Saleem, M. Din, and H. Mukhtar A Dietary Anthocyanidin Delphinidin Induces Apoptosis of Human Prostate Cancer PC3 Cells In vitro and In vivo: Involvement of Nuclear Factor-{kappa}B Signaling Cancer Res., October 15, 2008; 68(20): 8564 - 8572. [Abstract] [Full Text] [PDF]

				N. Khan, F. Afaq, D. N. Syed, and H. Mukhtar Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells Carcinogenesis, May 1, 2008; 29(5): 1049 - 1056. [Abstract] [Full Text] [PDF]